Immunovant (IMVT) to Post Earnings on Thursday

Posted by Brian Himes on Aug 4th, 2026

Immunovant (NASDAQ:IMVT – Get Free Report) will likely be announcing its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect Immunovant to post earnings of ($0.6290) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2027 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Immunovant (NASDAQ:IMVT – Get Free Report) last posted its earnings results on Wednesday, May 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.13). During the same period in the previous year, the company posted ($0.64) EPS. On average, analysts expect Immunovant to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunovant Price Performance

Shares of IMVT stock traded up $0.84 on Tuesday, hitting $39.35. The stock had a trading volume of 182,523 shares, compared to its average volume of 1,553,913. The business has a 50 day moving average of $36.74 and a 200 day moving average of $30.25. Immunovant has a 12-month low of $14.32 and a 12-month high of $41.23. The stock has a market cap of $8.12 billion, a price-to-earnings ratio of -14.16 and a beta of 0.77.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Citigroup upped their price objective on shares of Immunovant from $57.00 to $61.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunovant in a research report on Monday, July 6th. Truist Financial boosted their target price on Immunovant from $23.00 to $30.00 and gave the stock a “hold” rating in a research note on Friday, May 22nd. Bank of America upped their target price on Immunovant from $32.00 to $43.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Finally, Sanford C. Bernstein raised Immunovant to a “hold” rating in a report on Wednesday, July 29th. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $42.11.

Check Out Our Latest Report on Immunovant

Insiders Place Their Bets

In other news, COO Melanie Gloria sold 2,036 shares of the company’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $39.55, for a total transaction of $80,523.80. Following the transaction, the chief operating officer owned 222,357 shares of the company’s stock, valued at $8,794,219.35. This represents a 0.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Tuyl Christopher Van sold 1,206 shares of the stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $39.55, for a total value of $47,697.30. Following the transaction, the insider owned 179,391 shares of the company’s stock, valued at $7,094,914.05. The trade was a 0.67% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 324,810 shares of company stock valued at $11,350,166. Company insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Immunovant

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. lifted its holdings in Immunovant by 16.0% during the fourth quarter. Invesco Ltd. now owns 88,857 shares of the company’s stock valued at $2,259,000 after purchasing an additional 12,255 shares during the last quarter. Empowered Funds LLC raised its position in shares of Immunovant by 4.5% in the fourth quarter. Empowered Funds LLC now owns 14,175 shares of the company’s stock valued at $360,000 after purchasing an additional 610 shares during the period. XTX Topco Ltd raised its position in shares of Immunovant by 91.2% in the fourth quarter. XTX Topco Ltd now owns 33,122 shares of the company’s stock valued at $842,000 after purchasing an additional 15,795 shares during the period. VARCOV Co. bought a new stake in shares of Immunovant in the fourth quarter valued at approximately $404,000. Finally, Virtus Investment Advisers LLC lifted its stake in shares of Immunovant by 41.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 10,069 shares of the company’s stock valued at $256,000 after buying an additional 2,931 shares in the last quarter. 47.08% of the stock is currently owned by institutional investors.

About Immunovant

(Get Free Report)

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.